ライフサイエンスコーパス: radiosurgery

1 induced to undergo apoptosis by gamma knife radiosurgery.

2 deficits appeared more than 28 months after radiosurgery.

3 patients (2 percent) within four years after radiosurgery.

4 ical patients, 6-12 wk after radiotherapy or radiosurgery.

5 treated by conventional radiotherapy and/or radiosurgery.

6 nventional radiation as well as stereotactic radiosurgery.

7 craniotomy followed by adjuvant stereotactic radiosurgery.

8 selling patients on Gamma Knife stereotactic radiosurgery.

9 application will be image guidance in proton radiosurgery.

10 e surgical bed was treated with stereotactic radiosurgery.

11 , whole-brain radiotherapy, and stereotactic radiosurgery.

12 cant associations in studies of stereotactic radiosurgery.

13 dverse events were noted during or after the radiosurgery.

14 T), with or without surgery, or stereotactic radiosurgery.

15 ation, radiofrequency ablation, and recently radiosurgery.

16 etastases treated primarily with gamma knife radiosurgery.

17 5-mm value for conventional radiotherapy and radiosurgery.

18 e measured before treatment with gamma knife radiosurgery.

19 herapy, surgical resection, and stereotactic radiosurgery.

20 9 brain metastases treated with stereotactic radiosurgery (1-4 fractions) was performed.

21 nitial sites (surgery: 59% to 27%, P < .001; radiosurgery: 31% to 19%, P = .040) and at new sites (su

22 at new sites (surgery: 42% to 23%, P = .008; radiosurgery: 48% to 33%, P = .023).

23 73 metastases at 20 weeks after stereotactic radiosurgery; 61% maintained local control at 2 years.

24 ularly image-guided surgery and stereotactic radiosurgery, allows clinicians who are focused on the t

25 ion, neurosurgical excision, or stereotactic radiosurgery alone or in combination).

26 ons--167 were assigned WBRT and stereotactic radiosurgery and 164 were allocated WBRT alone.

27 uggests the long-term safety of stereotactic radiosurgery and could support physicians counselling pa

28 can include surgical excision, stereotactic radiosurgery and embolization.

29 interstitial brachy-therapy or stereotactic radiosurgery and is associated with a significantly lowe

30 lation, radiofrequency ablation, gamma knife radiosurgery and MVD.

31 0 to 2 were treated with complete surgery or radiosurgery and randomly assigned to adjuvant WBRT (30

32 ty-three AVM patients who were evaluated for radiosurgery and underwent multi-parametric MRI/MRA were

33 Of 359 patients, 199 underwent radiosurgery, and 160 underwent surgery.

34 normal in 76 percent of the patients before radiosurgery, and 20 percent had useful hearing.

35 ts (47 percent) were employed at the time of radiosurgery, and 37 (69 percent) remained so.

36 apy (WBRT), surgical resection, stereotactic radiosurgery, and chemotherapy.

37 d on indications for resection, stereotactic radiosurgery, and fractionated radiotherapy for patients

38 w brain lesion was treated with stereotactic radiosurgery, and he began systemic therapy with ipilimu

39 nal treatment planning systems, stereotactic radiosurgery, and intensity modulated radiation therapy

40 scular embolisation techniques, stereotactic radiosurgery, and microsurgery, allowing effective multi

41 nsity-modulated radiotherapy, brachytherapy, radiosurgery, and photodynamic therapy for recurrent hig

42 on therapy, surgical resection, stereotactic radiosurgery, and systemic therapy.

43 lan-Meier plots of survival from the date of radiosurgery, and univariate and multivariate analyses.

44 ch as whole-brain radiotherapy, stereotactic radiosurgery, and/or surgical resection.

45 Although surgery or stereotactic radiosurgery are highly effective local treatments for a

46 s) by neurosurgical excision or stereotactic radiosurgery are imprecise and vary between studies.

47 Surgery and radiosurgery are only local therapies and the patients f

48 The goals of radiosurgery are the long-term prevention of tumor growt

49 fects, especially important for stereotactic radiosurgery, are unknown.

50 eb 1, 2020, reporting the use of gamma knife radiosurgery as primary treatment for uveal melanoma or

51 The incidence of stereotactic radiosurgery-associated intracranial malignancy remains

52 as to estimate the incidence of stereotactic radiosurgery-associated intracranial malignancy, includi

53 %) of 4905 patients was considered a case of radiosurgery-associated intracranial malignancy, resulti

54 6 per 100 000 patient-years (0.11-11.17) for radiosurgery-associated intracranial malignancy.

55 Overall incidence of radiosurgery-associated malignancy was 6.80 per 100 000

56 Furthermore, small volume radiosurgery at different dose levels induced vascular,

57 ge, 0.02-0.18 cm(3)) undergoing stereotactic radiosurgery at one institution were included.

58 68 patients who had Gamma Knife stereotactic radiosurgery between Aug 14, 1987, and Dec 31, 2011, in

59 rapy (WBRT) or WBRT followed by stereotactic radiosurgery boost.

60 d symptoms from perilesional edema requiring radiosurgery, but all three patients remained on commerc

61 As an alternative, radiosurgery can be done for small tumours, or fractiona

62 sinus lesions and sellar lesions (for which radiosurgery can be offered as adjuvant or in certain ca

63 Radiosurgery can provide long-term control of acoustic n

64 ticentre, cohort study at five international radiosurgery centres (Na Homolce Hospital, Prague, Czech

65 calization and multiplicity make surgery and radiosurgery challenging and morbidity is often consider

66 in preclinical CyberKnife-based stereotactic radiosurgery (CK-SRS) of intracranial tumors is complica

67 livery techniques (hippocampal avoidance and radiosurgery) compared with whole-brain radiotherapy rep

68 The paradigm shift resulting from radiosurgery continues to alter the landscape of related

69 of targeted agents or ICIs with stereotactic radiosurgery could further improve the response rates an

70 Celiac plexus radiosurgery could potentially be a non-invasive palliat

71 medium-sized vestibular schwannoma, upfront radiosurgery demonstrated a significantly greater tumor

72 uated 162 consecutive patients who underwent radiosurgery for acoustic neuromas between 1987 and 1992

73 atients were of any age, and had Gamma Knife radiosurgery for arteriovenous malformation, trigeminal

74 The use stereotactic radiosurgery for brain metastases has expanded recently

75 derwent linear accelerator-based stereotaxic radiosurgery for brain metastases identified by computed

76 tic factors in patients treated with robotic radiosurgery for brain metastases irrespective of primar

77 view the recent publications of stereotactic radiosurgery for brain tumors.

78 herapy, and the role of upfront stereotactic radiosurgery for BrM.

79 s predicting the outcomes after stereotactic radiosurgery for cerebral arteriovenous malformations (A

80 first multi-institutional phase III trial of radiosurgery for patients with brain metastases to numer

81 nally, as radiation therapy and stereotactic radiosurgery for pituitary tumors gains more widespread

82 Currently, radiosurgery for these lesions produces similar results.

83 Survival after radiosurgery for three or more metastases was similar to

84 , outcomes, and complications of gamma knife radiosurgery for uveal melanomas and metastases.

85 k UM who underwent fractionated stereotactic radiosurgery (fSRS) treatment utilizing a novel Linear A

86 terventional-Vascular, Radionuclide Studies, Radiosurgery, Gamma Knife, Cyberknife, SPECT, Instrument

87 ogic complication resulting from gamma knife radiosurgery (GKRS) has not yet been reported.

88 icacy and safety of multisession gamma knife radiosurgery (GKRS) in benign, well-circumscribed tumors

89 ining the efficacy and safety of Gamma Knife radiosurgery (GKS) in treating patients with cerebral ca

90 was 0.87 (95% CI, 0.66-1.15) in the upfront radiosurgery group and 1.51 (95% CI, 1.23-1.84) in the w

91 vival advantage in the WBRT and stereotactic radiosurgery group for patients with a single brain meta

92 In the upfront radiosurgery group, 1 participant (2%) received repeated

93 In the radiosurgery group, 100 patients were allocated to OBS,

94 Radiosurgery has achieved satisfactory obliteration of d

95 lanning made in the past decade, gamma knife radiosurgery has become more and more an established tre

96 Radiosurgery has been recently utilized in the treatment

97 Recently, stereotactic radiosurgery has emerged as an increasingly important al

98 te its controversial beginning, stereotactic radiosurgery has rapidly gained acceptance among neurosu

99 Literature on extensive intracranial radiosurgery has unequivocally demonstrated the favorabl

100 Recent publications of stereotactic radiosurgery have increased our understanding of the use

101 e background of stereotactic one-day session radiosurgery, how the comparison in the difference betwe

102 used in oncology, can be a powerful tool for radiosurgery in cardiac diseases.

103 ry body melanoma treated with single-session radiosurgery in the last decade.

104 inform further investigation of using spine radiosurgery in the setting of oligometastases, where du

105 luate the safety and efficacy of gamma knife radiosurgery in this setting.

106 riteria (n=27 whole-brain radiotherapy; n=12 radiosurgery), including six studies evaluating combined

107 Existing therapeutic options, surgery and radiosurgery, including new data on the latter will be r

108 Radiosurgery is a promising new technology, but is still

109 Radiosurgery is an effective adjuvant therapy against me

110 Gamma knife radiosurgery is an efficacious primary method of treatin

111 ement of sporadic vestibular schwannoma with radiosurgery is becoming increasingly common globally; h

112 ted radiotherapy or stereotactic single-dose radiosurgery is increasing for meningiomas that are inco

113 Gamma ventral capsulotomy (GVC) radiosurgery is intended to minimize side effects while

114 sidered radiotherapy resistant, stereotactic radiosurgery is recommended; if the BMs are greater than

115 Gamma knife radiosurgery is regarded as the gold-standard stereotact

116 or concern of patients who have stereotactic radiosurgery is the long-term risk of having a secondary

117 Stereotactic radiosurgery is the principal alternative to microsurgic

118 r redo transsphenoidal surgery, stereotactic radiosurgery) is limited by the inability of MRI to accu

119 tomy as treatment for localized disease, and radiosurgery may be as effective as surgical resection i

120 Stereotactic radiosurgery may offer a survival advantage (in a select

121 d 5.4 (95% CI 4.5 to 6.4) after stereotactic radiosurgery (median follow-up 4.1 years).

122 s regarded as the gold-standard stereotactic radiosurgery modality for the treatment of intracranial

123 ts were randomized to receive either upfront radiosurgery (n = 50) or to undergo a wait-and-scan prot

124 dy shows that adjuvant WBRT after surgery or radiosurgery of a limited number of brain metastases fro

125 RT) with observation after either surgery or radiosurgery of a limited number of brain metastases in

126 of functional independence after surgery or radiosurgery of brain metastases.

127 er to reduce dose to normal brain tissue for radiosurgery of multiple metastases with single-isocente

128 ived 13.5-18-Gy single-fraction stereotactic radiosurgery; one received 19.8 Gy in three fractions, o

129 Treatment concepts combining surgery and radiosurgery or fractionated radiotherapy, which enable

130 ed symptomatology yet capsulotomy either via radiosurgery or radiofrequency ablation has in some pati

131 After radiosurgery or surgery of a limited number of brain met

132 nt data were available to assess gamma-knife radiosurgery or vagal nerve stimulation.

133 stibular schwannoma recommend either upfront radiosurgery or waiting to treat until tumor growth has

134 total of 549 (14.0%) underwent stereotactic radiosurgery or whole brain radiotherapy for breast canc

135 uided linear accelerator (MR-LINAC), robotic radiosurgery, or cobalt stereotactic unit.

136 a large tumor, single-fraction stereotactic radiosurgery, or use of more than 6 Gy per fraction.

137 provide the best possible predictions of AVM radiosurgery outcomes of any method to date, identify a

138 A variety of heterogeneous radiotherapy and radiosurgery phantom configurations were used for valida

139 Stereotactic radiosurgery planning for cerebral arteriovenous malform

140 Clinical validation of their utility in radiosurgery planning is warranted.

141 roscopy, radio pharmacy, ophthalmic coating, radiosurgery, production of most types of electric lamps

142 We aimed to assess whether stereotactic radiosurgery provided any therapeutic benefit in a rando

143 asone followed by pre-operative stereotactic radiosurgery (pSRS) and resection (n= 13 per arm).

144 front radiosurgery (wait-and-scan to upfront radiosurgery ratio, 1.73; 95% CI, 1.23-2.44; P = .002).

145 y for focal therapy of BrM with stereotactic radiosurgery; reducing the toxicity and improving patien

146 Gamma knife radiosurgery remains a compelling treatment for lesions

147 tumour in patients treated with stereotactic radiosurgery remains low at long-term follow-up, and is

148 tula Outcomes Research and the International Radiosurgery Research Foundation data.

149 The safety, efficacy, and morbidity of radiosurgery (RS) must be established before it can be o

150 Retrospective radiosurgery (RS) reports found no survival difference w

151 he capabilities of image-guided stereotactic radiosurgery, separation surgery, vertebroplasty, and mi

152 After resection of a brain metastasis, SRS radiosurgery should be considered one of the standards o

153 WBRT and stereotactic radiosurgery should, therefore, be standard treatment fo

154 diation Therapy, Radiation Therapy/Oncology, Radiosurgery, Skull Base, Spine, Technology Assessment S

155 on behalf of the International Stereotactic Radiosurgery Society.

156 nd no systemic therapy options, stereotactic radiosurgery (SRS) alone should be offered to patients w

157 tion can be challenging, making stereotactic radiosurgery (SRS) an attractive alternative for symptom

158 Although stereotactic radiosurgery (SRS) and endovascular embolization are use

159 h brain metastases who received stereotactic radiosurgery (SRS) and/or non-SRS radiation therapies wi

160 achine learning to predict post-stereotactic radiosurgery (SRS) brain metastasis (BM) progression, bu

161 ain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) delivered only to the radiographicall

162 Adjuvant stereotactic radiosurgery (SRS) enhances the local control of resecte

163 The optimal use of up-front stereotactic radiosurgery (SRS) for brain metastases (BM) in patients

164 s recommend surgery followed by stereotactic radiosurgery (SRS) for lesions >3 cm, smaller lesions (<

165 stitution, 97% of whom received stereotactic radiosurgery (SRS) for local treatment of BM.

166 ain radiation therapy (WBRT) to stereotactic radiosurgery (SRS) for the control of brain-tumours outw

167 explore the use of Gamma Knife stereotactic radiosurgery (SRS) for this common problem.

168 ic events in patients receiving Stereotactic Radiosurgery (SRS) for unruptured bAVMs.

169 Preoperative stereotactic radiosurgery (SRS) has been demonstrated as a feasible a

170 Stereotactic radiosurgery (SRS) has been the cornerstone of managemen

171 Stereotactic radiosurgery (SRS) has evolved as widely accepted treatm

172 Stereotactic radiosurgery (SRS) has proven an effective tool for the

173 Stereotactic radiosurgery (SRS) is an established, effective therapy

174 Within the guideline, stereotactic radiosurgery (SRS) is recommended for patients with East

175 Stereotactic radiosurgery (SRS) is the only local therapy for BSM, bu

176 ective series, neurosurgery and stereotactic radiosurgery (SRS) may prolong survival in patients with

177 ctional doses that characterize stereotactic radiosurgery (SRS) or radiotherapy (SRT), specifically i

178 did this study to determine if stereotactic radiosurgery (SRS) to the surgical cavity improved time

179 However, stereotactic radiosurgery (SRS) to the surgical cavity is widely used

180 are manually identified during stereotactic radiosurgery (SRS) treatment planning, which is time con

181 s patient outcomes treated with stereotactic radiosurgery (SRS) versus conservative management.

182 The concept of stereotactic radiosurgery (SRS) was first described by Lars Leksell i

183 nd includes surgical resection, stereotactic radiosurgery (SRS), and whole-brain radiation therapy (W

184 sphenopalatine ganglion (SPG), stereotactic radiosurgery (SRS), deep brain stimulation (DBS) or micr

185 Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and

186 umor control in the brain after stereotactic radiosurgery (SRS), yet because of its association with

187 with brain metastases following stereotactic radiosurgery (SRS).

188 ived radiotherapy to the brain (stereotactic radiosurgery [SRS] or whole-brain radiotherapy [WBRT]),

189 nts with 1 to 3 brain metastases amenable to radiosurgery, SRS alone may be a preferred strategy.

190 been the integration of spinal stereotactic radiosurgery (SSRS), allowing delivery of tumoricidal ra

191 gery, whole-brain radiotherapy, stereotactic radiosurgery, supportive or palliative care, and interdi

192 longed course of WBRT, surgery, stereotactic radiosurgery, systemic therapy, or a combination.

193 otherapy and surgery to include stereotactic radiosurgery, targeted therapies and immunotherapies, wh

194 urrently, surgical excision and stereotactic radiosurgery, the primary treatment options, pose risks

195 Radiosurgery to synchronous intact BMs was allowed.

196 ed optic neuropathy are infrequent following radiosurgery to these areas, and perhaps radiation-induc

197 ence treatment in patients with stereotactic radiosurgery-treated metastases.

198 t-and-scan group, 21 patients (42%) received radiosurgery upon tumor growth, 1 (2%) underwent salvage

199 group, 1 participant (2%) received repeated radiosurgery upon tumor growth, 2 (4%) needed salvage mi

200 derived from the techniques of stereotactic radiosurgery used to treat lesions in the brain and spin

201 ts randomized to sham GVC received simulated radiosurgery using the same equipment.

202 re necessary to better define the utility of radiosurgery versus surgery in the management of patient

203 e reduction in patients treated with upfront radiosurgery (wait-and-scan to upfront radiosurgery rati

204 The median survival time after stereotactic radiosurgery was 53 weeks and correlated with systemic d

205 Radiosurgery was believed to have been successful by all

206 from Europe and the USA, after stereotactic radiosurgery was found to be similar to the risk of deve

207 Rates of response to stereotactic radiosurgery were calculated.

208 ular tumours, or other forms of stereotactic radiosurgery were excluded to reduce heterogeneity.

209 s, even when tumor apoptosis was induced via radiosurgery, which leads to efficient "loading" of the

210 The only potential treatment is surgery/radiosurgery, which often results in loss of function of

211 ent are typically utilized: pharmacological, radiosurgery with gamma radiation, and external beam rad

212 Five minipigs received focal stereotactic radiosurgery with single large doses of 40-100 Gy to 5-7